Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of Pevonedistat in Combination With Induction Chemotherapy for Adolescent and Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia

Trial Profile

A Phase I Trial of Pevonedistat in Combination With Induction Chemotherapy for Adolescent and Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Pevonedistat (Primary) ; Dexamethasone; Doxorubicin; Pegaspargase; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Nov 2018 Planned End Date changed from 1 Sep 2024 to 1 Mar 2025.
    • 01 Nov 2018 Planned primary completion date changed from 1 Sep 2023 to 1 Mar 2024.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top